We are pleased to announce that Lewis Gruber was recently named to the Aging Analytics Agency’s list of 1000 Longevity Leaders recognized in the research and academia sector for his work with SIWA Therapeutics. Aging Analytics is the longest-running and most comprehensive interactive platform of longevity professionals. The agency profiles public and private-sector influencers whose work in business, science, policy, philanthropy, or thought-leadership is instrumental in the longevity landscape.
SIWA Therapeutics is excited to announce that we are doing our part in the global fight against COVID-19. Our humanized monoclonal antibody targets cells with an abnormally high level of glycolysis (known as the Warburg effect in cancer) and oxidative stress. This category includes, among other things, virally infected cells, including those infected by COVID-19. Read more below: http://biospace.com/article/chicago-biotech-company-testing-its-monoclonal-antibody-to-treat-covid-19/
Our founder and Chief Scientific Officer, Lewis Gruber recently spoke with Jim Dallke, Senior Editor of AmericanInno and contributor to American City Business Journals about SIWA Therapeutic’s groundbreaking work to defeat aging and age-related diseases. Read more here: https://www.bizjournals.com/chicago/news/2020/03/25/startup-siwa-therapeutics-aims-to-find-a-cure-for.html
Lewis and Misty Gruber discuss how SIWA 318H, the company’s humanized monoclonal antibody, binds to a biomarker of oxidative stress found on senescent cells and cancer cells as well as dysfunctional cells in general. https://www.lifespan.io/news/lewis-gruber-senotherapeutics/